# Effect of Telemedicine Support for Intraoperative Anaesthesia Care on Postoperative Outcomes: The TECTONICS Randomised Clinical Trial

Short title:

An RCT of anaesthetic telemedicine support.

<sup>1</sup>Christopher R King, MD, PhD 0000-0002-4574-8616

<sup>1</sup>Bradley A. Fritz, MD 0000-0002-7239-8877

<sup>1</sup>Stephen H. Gregory, MD

<sup>1</sup>Thaddeus P. Budelier, MD, MSF 0000-0002-8427-5583

<sup>1</sup>Arbi Ben Abdallah, PhD 0000-0002-1287-0455

<sup>1</sup>Alex Kronzer, 1

<sup>1</sup>Daniel L. Helsten, MD

<sup>1,5</sup>Brian Torres. DNP

<sup>1</sup>Sherry L. McKinnon, MS

<sup>1</sup>Sandhya Tripathi, PhD 0000-0003-3992-2283

<sup>1,2</sup>Mohamed Abdelhack, PhD 0000-0002-6753-3237

<sup>1</sup>Shreya Goswami, MD

<sup>1</sup>Arianna Montes de Oca, MD

<sup>1</sup>Divya Mehta, MD

<sup>1</sup>Miguel A. Valdez, MD

<sup>1</sup>Evangelos Karanikolas, MD 0009-0007-2807-2208

<sup>1</sup>Omokhaye Higo, MD

<sup>1</sup>Paul Kerby, MD

<sup>1</sup>Bernadette Henrichs, PhD

<sup>3</sup>Troy S. Wildes, MD0000-0002-9042-571X

<sup>6</sup>Mary C. Politi, PhD

<sup>1,4</sup>Joanna Abraham, PhD

<sup>1</sup>Michael S. Avidan, MB BCh 0000-0001-6248-044X

## And the ACTFAST collaborator group.

<sup>1</sup>Department of Anesthesiology, Washington University School of Medicine in St Louis

<sup>2</sup>Krembil Centre for Neuroinformatics, Centre for Addiction and Mental Health, Toronto, ON

<sup>3</sup>Department of Anesthesiology, University of Nebraska Medical Center

<sup>4</sup>Institute for Informatics, Data Science and Biostatistics, Washington University School of Medicine in St Louis

<sup>5</sup>Barnes-Jewish College, Goldfarb School of Nursing in St. Louis

<sup>6</sup>Department of Surgery, Washington University School of Medicine in St Louis

Christopher R. King, MD, PhD 660 S. Euclid Avenue, MSC-8054-50-02 Washington University School of Medicine St Louis, Missouri 63110 (314) 273-7801 christopherking@wustl.edu

Christopherking@wustl.edu
NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

<sup>&</sup>lt;sup>1,4</sup>Thomas Kannampallil, PhD 0000-0003-4119-4836

WC: 2832/3000

Trial registration: https://www.clinicaltrials.gov/study/NCT03923699

Keywords: Telemedicine, decision support, remote monitoring, machine learning

#### **Abstract**

Background: Novel applications of telemedicine can improve care quality and patient outcomes. Telemedicine for intraoperative decision support has not been rigorously studied.

Methods: This single centre randomised clinical trial (clinicaltrials.gov NCT03923699) of unselected adult surgical patients was conducted between July 1, 2019 and January 31, 2023. Patients received usual care or decision support from a telemedicine service, the Anesthesiology Control Tower (ACT). The ACT provided real-time recommendations to intraoperative anaesthesia clinicians based on case reviews, machine-learning forecasting, and physiologic alerts. ORs were randomised 1:1. Co-primary outcomes of 30-day all-cause mortality, respiratory failure, acute kidney injury (AKI), and delirium were analysed as intention-to-treat.

Results: The trial completed planned enrolment with 71927 surgeries (35956 ACT; 35971 usual care). After multiple testing correction, there was no significant effect of the ACT vs. usual care on 30-day mortality [641/35956 (1.8%) vs 638/35971 (1.8%), risk difference 0.0% (95% CI -0.2% to 0.3%), p=0.96], respiratory failure [1089/34613 (3.1%) vs 1112/34619 (3.2%), risk difference -0.1% (95% CI -0.4% to 0.3%), p=0.96], AKI [2357/33897 (7%) vs 2391/33795 (7.1%), risk difference -0.1% (-0.6% to 0.4%), p=0.96], or delirium [1283/3928 (32.7%) vs 1279/3989 (32.1%), risk difference 0.6% (-2.0% to 3.2%), p=0.96]. There were no significant differences in secondary outcomes or in sensitivity analyses.

Conclusions: In this large RCT of a novel application of telemedicine-based remote monitoring and decision support using real-time alerts and case reviews, we found no significant differences in postoperative outcomes. Large-scale intraoperative telemedicine is feasible, and we suggest future avenues where it may be impactful.

WC: 248/300

#### Introduction

Tele-critical care (TCC), the use of remote monitoring and telemedicine to augment intensive care unit (ICU) services, <sup>1</sup> operates in most academic hospitals<sup>2</sup> and in nearly 20% of hospitals with ICU beds.<sup>3</sup> Although there are multiple TCC models, <sup>4</sup> contemporary TCC supports bedside teams through a combination of expert consultations, real-time review of emerging problems, continuous remote monitoring, encouragement of best practices, and facilitating communication. <sup>2</sup> TCC support improves care quality and patient outcomes by reducing and overcoming distractions to bedside clinicians. <sup>2,5</sup> Although effect size estimates from quasi-experimental TCC studies have been heterogeneous, <sup>6</sup> TCC has repeatedly been associated with improved patient outcomes. <sup>1,2</sup> However, no RCT data has shown a positive impact on patient outcomes.

Although seemingly a natural extension of the adoption of TCC, there are limited applications of or research evaluating remote monitoring models for intraoperative care. Existing case reports focus on intraoperative one-on-one video calls to support low-resource or remote locations. <sup>7–12</sup> This is surprising because critical care and anaesthesia care are closely related fields, with similar physiologic changes and monitoring technology. Like critical care settings, anaesthesia clinicians experience high cognitive load and distractions from complex, high-frequency data combined with procedures and documentation. Decision support from telemedicine may therefore have a similar beneficial role. <sup>13</sup>

Therefore, we hypothesized that remote monitoring and support via a telemedicine centre for anaesthesia clinicians similar to current tele-critical care delivery models would improve surgical patient outcomes. Towards this end, we developed the "Anesthesiology Control Tower" (ACT), <sup>14–16</sup> a telemedicine support service for anaesthesia clinicians in the OR. Key activities of the ACT included (a) reviewing the anaesthetic plans for higher-risk cases and communicating recommendations to the OR anaesthesia clinicians, (b) continuous monitoring of real-time data and alerts to assess patient deterioration (c) encouraging adherence to institutional protocols (e.g., hyperglycaemia management), and (d) assisting in crisis management and coordinating out-of-OR resources. A pilot and feasibility trial of the ACT (ACTFAST-3) showed the feasibility of using a real-time telemedicine system for intraoperative decision support and collaborative decision-making. <sup>15</sup> Additional design and process changes were made based on studies assessing the workflow of ORs and ACT <sup>14</sup> and patient input. <sup>17</sup>

The objective of this clinical trial, Telemedicine Control Tower for the OR: Navigating Information, Care, and Safety (TECTONICS), was to evaluate the impact of remote monitoring and decision support by the ACT on postoperative patient outcomes.

#### **Methods**

## Study design and ethics

TECTONICS was a pragmatic, randomised parallel, single-centre, superiority trial conducted at Barnes-Jewish Hospital (BJH) and Washington University School of Medicine in St. Louis, MO, USA. The institutional review board at Washington University approved the study with a waiver of informed consent. TECTONICS's protocol and statistical analysis plan were registered at clinicaltrials.gov (NCT03923699). A data safety monitoring board (DSMB) met quarterly but conducted no interim efficacy analyses.

## Setting and population

BJH is an adult urban tertiary centre. During the study (July 1, 2019 to January 30, 2023), 59 ORs were included, with at most 54 concurrent rooms. These excluded non-surgical procedure suites and obstetrics. The site used a medical-direction model for anaesthesia care: no more than 4, and usually 2-3, certified registered nurse anaesthetists (CRNA) or 1-2 resident physicians per anaesthesiologist. We enrolled all adult patients (>=18 years) with surgery starting between 06:15 and 16:00 weekdays with anaesthesia services, including emergency cases. The ACT was closed, and patients excluded on days with clinical staff shortages (see Supplement). Patients were followed for 30 days to ascertain outcomes.

## Intervention: Anesthesiology Control Tower (ACT)

Patients in the intervention group received ACT-enhanced care; we have previously described the development, preliminary evaluation and functioning of the ACT. <sup>14–16</sup> The ACT was a remote monitoring suite with real-time data feeds from the Electronic Health Record (EHR) and the AlertWatch:OR (Ann Arbor, Michigan) informatics platform. ACT screens displayed a customized AlertWatch:OR interface with a dashboard summarizing all active surgeries. The dashboard contained an overall patient complexity measure, current data-driven alerts, and links to patient-specific views of current data and trends (Supplemental Figure 1). To assist with prioritizing cases for review and quantifying patient risks for ACT-OR communication, a web application displayed machine learning predictions of individual patient risk of several major adverse events (Supplemental Figure 2). <sup>18–21</sup> The implementation and validation of this web application is described elsewhere. <sup>22</sup> ACT staff also used the Epic EHR to access patient information.

The supplement contains the ACT manual of procedures. The ACT was staffed by an anaesthesiologist, a research coordinator, and up to 3 additional personnel (CRNA, student registered nurse anaesthetist, anaesthesiology resident). ACT activities focused on reviewing anaesthetic plans in active cases selected at the anaesthesiologist's discretion, identifying important issues, and sending a summary of risk-mitigation recommendations and applicable protocols to the intraoperative anaesthesia clinicians. At their discretion, ACT clinicians reacted to alerts in the Alertwatch:OR dashboard, either sending recommendations to the intraoperative clinician or silencing the alert. The ACT contacted clinicians via Epic's Secure Chat messaging or hospital-issued phones.

Staffing and monitoring were unchanged in the usual care group. ACT staff reviewed anaesthesia plans and alerts in usual-care patients, but the results were not communicated to intraoperative clinicians. ACT staff contacted intraoperative clinicians in usual-care ORs only in situations with potential imminent danger to patients, such as the failure to deliver inhaled anaesthetic agents.

## Randomisation and Blinding

Each day, operating rooms (and all patients nested in each OR) were 1:1 randomised to intervention or usual care (cluster randomisation by operating room and day). Randomisation was calculated and displayed in the ACT dashboard at midnight without considering the number of cases scheduled in each room (including zero). Therefore, the realized randomisation ratio of patients varied. Only the first case for a patient in a 30-day window was analysed; cases 30-days after an index surgery were eligible for analysis. Outcome assessors and patients were blinded to assignments. Intraoperative clinicians were blinded unless contacted by the ACT.

#### **Patient Outcomes**

Four co-primary outcomes were ascertained: 30-day all-cause mortality, postoperative respiratory failure, postoperative acute kidney injury (AKI), and postoperative delirium. These outcomes were chosen to represent

major patient-oriented complications. Secondary outcomes were a composite (sum of co-primary outcomes), hyperglycaemia, hypotension, normothermia, low peak airway pressures, avoidance of gaps in volatile anaesthetic delivery, and efficient use of volatile anaesthetics, which are operationalized in the supplement. Alternative specifications are also defined in the supplement. All outcomes were incident. Definitions, missing data handling, and EHR measurements used for primary and secondary outcomes are contained in the Supplement. Data was extracted from the EHR in two waves (2019-2020, 2021-2023).

#### Sample size calculation

Sample size was calculated per the protocol with a planned enrolment of 40,000 over 4 years. <sup>23</sup> As a low-risk health system intervention, there was no clear minimally clinically important difference. Due to a larger than expected number of eligible patients, during the first year of the study, the principal investigator and DSMB agreed to expand the study population to 80,000 to allow detection of smaller but potentially meaningful intervention effects.


## Statistical analysis

Relative risks for all primary outcomes were calculated with a Poisson generalized estimating equation (GEE) model clustering on OR and day (the unit of randomisation) and HC1 adjustment to standard errors. <sup>24</sup> Risk differences were calculated with a linear-link GEE model using the same clustering. Bonferroni adjusted 95% and 99.5% confidence intervals were calculated. Two-sided p-values were adjusted for multiple testing <sup>25</sup> with an alpha of 0.005. <sup>26</sup> Secondary outcomes were analysed in the same manner; a linear link GEE model was used for non-binary outcomes. All analyses were conducted intention-to-treat (ignoring actual communication between the ACT and OR) among all patients with ascertainable outcomes. Planned subgroup and sensitivity analyses are described in the supplement. Analysis used R version 4.3.0; a docker file with package versions and analysis code is available at <a href="https://github.com/cryanking/tectonics\_deident">https://github.com/cryanking/tectonics\_deident</a>.

# Intervention monitoring

ACT staff logged case reviews, alert interpretation, and OR communication (OR interventions) in the AlertWatch:OR web interface using discrete fields and free-text comments. Due to a database malfunction, ACT logs of case reviews, ACT to OR communication, and alert interpretations were lost for a block of 67/833 study days; we report contacts and alerts from discrete data on days with intact logs.

Figure 1 displays the included population. The trial completed its targeted enrolment with 71927 surgeries included in the primary analysis, with 35956 cases (18091 clusters) allocated to intervention and 35971 cases (17907 clusters) allocated to usual care. There were minimal differences in comorbidities, functional status, surgery class, or other characteristics (Table 1). The mean patient age was 57 ranging from 18 to 103; patients were 49% male and 51% female. Patient races were white (70%) or Black (20%), with 9% unrecorded or belonging to multiple groups. A wide variety of surgery types were included; orthopaedics was the most common high-level grouping (18%).



**Figure 1**: Patient flow and exclusion criteria. ACT hours = 0615 to 1600. AKI =acute kidney injury. CAM-ICU = confusion assessment method for the ICU. "no flowsheet data" = no data returned for specified medical record number.

Variable	Intervention, n=35956	Usual care, n=35971
Age	57.3 (16.8)	57.3 (17)
Atrial Fib	3009/33002 (9.1%)	3004/32902 (9.1%)
Anaemia	9270/33002 (28.1%)	9295/32902 (28.3%)
Asthma	3686/33002 (11.2%)	3734/32902 (11.3%)
CAD	4300/33002 (13%)	4276/32902 (13%)
Cancer	3751/33002 (11.4%)	3732/32902 (11.3%)
CKD	4469/33002 (13.5%)	4483/32902 (13.6%)
ESRD	1511/33002 (4.6%)	1561/32902 (4.7%)
COPD	3478/33002 (10.5%)	3448/32902 (10.5%)
Dementia	1060/33002 (3.2%)	998/32902 (3%)
Diabetes	7879/33002 (23.9%)	7850/32902 (23.9%)
Stroke	1913/33002 (5.8%)	1940/32902 (5.9%)
VTE	3284/33002 (10%)	3374/32902 (10.3%)
OSA	5953/33002 (18%)	5825/32902 (17.7%)
HTN	17204/33002 (52.1%)	16563/32902 (50.3%)
Race		
American Indian or Alaska Native	96/35956 (0.3%)	103/35971 (0.3%)
Asian	418/35956 (1.2%)	390/35971 (1.1%)
Black or African American	7035/35956 (19.6%)	6972/35971 (19.4%)
Other Pacific Islander	59/35956 (0.2%)	56/35971 (0.2%)
Unknown or Other	3222/35956 (9%)	3380/35971 (9.4%)
White	25126/35956 (69.9%)	25070/35971 (69.7%)
Sex		
Female	18329/35956 (51%)	18307/35971 (50.9%)

Male	17625/35956 (49%)	17660/35971 (49.1%)
Unknown or Other	2/35956 (0%)	4/35971 (0%)
Functional Capacity		
<4 METs	10033/35956 (27.9%)	10004/35971 (27.8%)
4-6 METs	16714/35956 (46.5%)	16375/35971 (45.5%)
6-10 METs	781/35956 (2.2%)	746/35971 (2.1%)
>10 METs	133/35956 (0.4%)	132/35971 (0.4%)
Unknown or Unable to Assess	8295/35956 (23.1%)	8714/35971 (24.2%)
ASA-PS		
1	1361/35956 (3.8%)	1352/35971 (3.8%)
2	11483/35956 (31.9%)	11398/35971 (31.7%)
3	15414/35956 (42.9%)	15462/35971 (43%)
4	3204/35956 (8.9%)	3228/35971 (9%)
5	93/35956 (0.3%)	99/35971 (0.3%)
Unknown or Other	4401/35956 (12.2%)	4432/35971 (12.3%)
Service		
Cardiothoracic	3459/35956 (9.6%)	3487/35971 (9.7%)
Colorectal	1131/35956 (3.1%)	1133/35971 (3.1%)
General and Trauma	4571/35956 (12.7%)	4465/35971 (12.4%)
Gynaecology	4207/35956 (11.7%)	4052/35971 (11.3%)
Misc procedures, GI, Ophthalmology	2224/35956 (6.2%)	2574/35971 (7.2%)
Neurosurgery	2725/35956 (7.6%)	2615/35971 (7.3%)
Orthopaedics	6352/35956 (17.7%)	6417/35971 (17.8%)
Otolaryngology	3025/35956 (8.4%)	2960/35971 (8.2%)
Plastics	780/35956 (2.2%)	792/35971 (2.2%)

Transplant	1177/35956 (3.3%)	1201/35971 (3.3%)
Urology	3850/35956 (10.7%)	3873/35971 (10.8%)
Vascular	2455/35956 (6.8%)	2402/35971 (6.7%)

**Table 1**: Baseline characteristics of patients. Mean (SD) or k/N (%), Groups with less than 100 patients not shown (merged into "Other"). Atrial Fib = atrial fibrillation, CAD = coronary artery disease, CKD = chronic kidney disease, ESRD = end stage renal disease, COPD = chronic obstructive pulmonary disease, VTE = venous thromboembolic disease, OSA = obstructive sleep apnoea, HTN = hypertension, METs = metabolic equivalents, ASA-PS = American Society of Anesthesiologists' physical status, GI = gastroenterology. Patients with more than one included surgery appear multiple times.


Supplementary Figures 3, 4, and 5 show enrolment rates and ascertainment rates of primary and secondary outcomes over time. Aside from a period of reduced surgical volume and limited staff availability during the COVID-19 pandemic (Supplementary Figure 6), recruitment and outcome ascertainment were consistent and not differential by study group. The low rate of ascertainment of incident delirium was anticipated because routine CAM-ICU measurement was performed only in some ICUs. Intervention and usual care groups were well separated with respect to ACT-OR contact: the ACT contacted 2039/32224 (6.3%) of intervention cases and 238/31938 (0.7%) of usual care cases regarding alerts. ACT clinicians reviewed anaesthesia plans on 7977/32224 (25%) intervention cases and 5680/31938 (18%) usual care cases. Denominators for ACT actions are smaller than the total because of a database malfunction affecting several months.

For the co-primary outcomes, there was no significant difference in 30-day mortality [ACT 641/35956 (1.8%) vs usual care 638/35971 (1.8%), risk difference 0.0% (95% CI -0.2% to 0.3%), relative risk 1.01 (95% CI 0.87 to 1.16), p=0.96], respiratory failure [ACT 1089/34613 (3.1%) vs usual care 1112/34619 (3.2%), risk difference -0.1% (95% CI -0.4% to 0.3%), RR 0.98 (95% CI 0.88 to 1.09), p=0.96], AKI [ACT 2357/33897 (7%) vs usual care 2391/33795 (7.1%), risk difference -0.1% (-0.6% to 0.4%), RR 0.98 (95% CI 0.91 to 1.06), p=0.96], or delirium [ACT 1283/3928 (32.7%) vs usual care 1279/3989 (32.1%), risk difference 0.6% (-2.0% to 3.2%), RR 1.02 (95% CI 0.94 to 1.11), p=0.96]. Table 2 shows event rates and effect estimates for primary and secondary outcomes. Figure 2 shows time trends in unadjusted quarterly event rates in usual care and intervention groups.

Outcome	Intervention	Usual Care	GEE coef (95% CI)	p value
Delirium	1283/3928 (32.7)	1279/3989 (32.1)	1.02 (0.94, 1.11)	0.96
Respiratory Failure	1089/34613 (3.1)	1112/34619 (3.2)	0.98 (0.88, 1.09)	0.96
AKI	2357/33897 (7)	2391/33795 (7.1)	0.98 (0.91, 1.06)	0.96
30-day mortality	641/35956 (1.8)	638/35971 (1.8)	1.01 (0.87, 1.16)	0.96
Secondary Outcomes				
On time Antibiotic redosing	5238/5496 (95.3)	5157/5415 (95.2)	1.00 (0.99, 1.01)	0.91
Normothermia	24851/31661 (78.5)	24537/31363 (78.2)	1.00 (0.99, 1.02)	0.91

Fraction time hypotensive	0.03 (0.08)	0.04 (0.08)	-0.00 (-0.00, 0.00)	0.91
Fraction time acceptable PIP	0.92 (0.22)	0.92 (0.21)	-0.00 (-0.01, 0.00)	0.91
Hyperglycaemia	1658/29005 (5.7)	1627/29063 (5.6)	1.02 (0.93, 1.12)	0.91
Anaesthetic delivery without gaps	27430/27743 (98.9)	27225/27511 (99)	1.00 (1.00, 1.00)	0.91
Efficient gas flow > 90%	18225/24398 (74.7)	18289/24370 (75)	1.00 (0.98, 1.01)	0.91

**Table 2**: Intention-to-treat effect estimates of the intervention. Missing due to either outcome data not present, or patient not eligible, such as outcome present at baseline. Usual care and intervention columns [yes/number measured (%)] or [mean (SD)] for continuous outcomes. GEE coefficients from clustered Poisson model (binary outcome) or linear model (continuous outcomes). 95% CI Bonferroni corrected for multiple testing. P-value by permutation (5000 permutations) corrected for multiple testing. Secondary outcomes defined in the supplement.



**Figure 2**: Primary outcome rates by treatment group over time. Bars = pointwise 95% confidence intervals from a linear GEE model using the same clustering as the primary analysis and HC1 adjustment. Data aggregated over 3-month intervals. Red dots = ACT, black = usual care.

After multiple testing correction, there were no significant differences by intervention group for any secondary outcome (Table 2). The results were consistent across alternative specifications, subgroup analysis, and sensitivity analyses (Supplement Tables 1-9).

Supplement Table 10 displays the frequency and reason for ACT interventions.

#### **Discussion**

This large (N=71927) randomised trial tested the hypothesis that compared to usual care, remote monitoring and telemedicine-based support from a novel Anesthesiology Control Tower using real-time alerts, machine learning risk identification, and in-depth case reviews for intraoperative anaesthesia clinicians would improve 4 key postoperative patient outcomes: 30-day mortality, respiratory failure, AKI, and delirium. We found no significant effects of randomisation to ACT support on any of the primary or secondary outcomes, nor did we find discordant results in subgroup or sensitivity analyses. Because mortality and respiratory failure are rare (Table 2) and multiple testing decreases certainty, confidence intervals on the effect sizes included some clinically meaningful values. However, for the more common outcomes (AKI and delirium) and secondary outcomes, the results excluded meaningful effect sizes (Table 2, Supplemental Table 9).

Comparison to prior trials. The only directly comparable study for synthesis is our pilot trial, ACTFAST-3, <sup>15</sup> which had similar findings regarding effects of the ACT on patient outcomes and process measures. Notably, ACTFAST-3 was smaller and designed to detect changes in process measures (temperature and glycaemic control). TECTONICS is also distinguished from ACTFAST-3 by having a stable intervention versus adaptation during implementation and the deployment of a machine learning risk-estimation tool. Our results should also be compared to Kheterpal et al., who quasi-experimentally studied the impact of the Alertwatch:OR application for intraoperative clinicians on anaesthesia process measures, finding that time with hypotension, inappropriately large tidal volumes, and costs improved. <sup>13</sup> Our results are therefore surprising given the most serious alerts were communicated to the intraoperative clinician, and that very few clinicians at the study site otherwise used Alertwatch:OR.

Our intervention is an adaptation of widely adopted strategies in tele-critical care. <sup>4</sup> Our results are therefore surprising given the positive association of TCC with ICU patient outcomes. <sup>6</sup> The study setting, an urban academic centre, also mirrors the settings in which TCC was most associated with improved patient outcomes. <sup>6</sup> However, there are no individual-level RCTs of TCC's effect on patient outcomes, and a variety of biases may have led to over-estimation of effects in the before-after studies which dominate tele-critical care's evidence base. A cluster-randomised trial of TCC with a lower risk of bias will be available soon. <sup>27</sup> The only randomised trial of TCC of which we are aware found effects on protocol adherence but not patient outcomes. <sup>5</sup> Importantly, because of the (nearly) patient level randomisation and contamination from shared clinicians, our analysis of TECTONICS does not capture benefits to outcomes due to overall improvements in protocol adherence, discussed below.

Strengths of TECTONICS include the low crossover rate, large and diverse population, low loss to follow up, and pragmatic design. TECTONICS was preceded by iterative development and a substantial pilot, making the intervention relatively mature. Because of the long period of ACTFAST-3 and TECTONICS (2017-2023), our analysis avoids threats to generalization from sustainability and acceptance from clinical stakeholders.

Several limitations could have led to underestimating the effects of the ACT. Although the population was large, the rate of contact between the ACT and eligible ORs was moderate (6.3%), so even a highly efficacious intervention (conditional on contact) would have had modest power. An exploratory analysis of only patients whom the ACT was likely to contact and other sources of heterogeneity is a future direction, but our planned subgroup analyses found no effect of the intervention. Hawthorne and contamination effects are also limitations. Clinicians at the study site were aware of ACT monitoring and received frequent messages regarding common issues. Although specific physiologic alerts did not affect usual care patients, the "audit and feedback" type effect on protocol adherence and optimization of common intraoperative issues likely spilled over, affecting both study arms. For example, an anaesthesiologist caring for diabetic patients in both arms of the study might improve glycaemia protocol adherence in both groups based on ACT messages. We initially planned a pre-post intervention analysis to elucidate these effects, but changes in the EHR and the concurrent COVID-19 pandemic made that infeasible. Secondary analyses will explore changes after the study to address this question. Although the recorded crossover' rate was low, the primary analysis likely does not reflect the effect of the most clinically-relevant interventions made by the ACT, because the study encouraged clinicians to intervene on usual care-group patients if serious time-sensitive alerts occurred (Supplemental Table 10). Finally, measurement error may have mitigated observed effects of the intervention. Two of our primary outcomes, delirium and respiratory failure, were derived from routinely collected bedside assessments, and

inaccuracies <sup>28</sup> in those data may have distorted our results. Deaths were identified from the EHR rather than governmental statistics and may miss some events after discharge if no follow-up was planned. AKI is likely under-detected due to selective measurement of postoperative creatinine. In none of these cases do we believe these errors to be differential between groups.

The study site was a tertiary academic centre, which limits the generalizability of the findings. Several aspects of the study site may explain the null result. The site's low supervision ratio allowed anaesthesiologists to closely monitor high-risk cases, reducing the impact of cognitive load and the opportunity to miss key data. Anaesthesia clinicians at the site sub-specialize, which tends to make them familiar with relevant protocols and best practices, <sup>29</sup> mitigating the relevance of the ACT's recommendations. The site's pre-anaesthesia clinic evaluated roughly 90% of patients, pre-emptively facilitating appropriate risk mitigation plans. <sup>19</sup> In settings without these redundant checks, a similar intervention may improve outcomes. Additionally, we evaluated a single set of physiologic alerts. The most common alerts were on topics only weakly related to the primary outcomes (Supplemental Table 10). Although we found these alerts to fit the needs of the ACT, alerts with more advanced detection of, for example, impending hypotension, may have larger effects.

## Summary

In this large RCT, we found that intraoperative telemedicine support for anaesthesia clinicians with case planning reviews and real-time alerts did not reduce 30-day mortality, respiratory failure, AKI, or delirium. Clinicians accepted telemedicine support, and we observed many safety and process-of-care interventions during its development and implementation, which suggests that intraoperative telemedicine should be further explored in other settings. Future work on similar telemedicine models should use multi-centre designs to detect effects mediated by quality improvement, avoid contamination due to time-critical alerts that cannot ethically be withheld from the intraoperative clinician, and explore alternative practice settings.

**Author Contributions**: All authors had full access to all the data in the study and agreed to submit it for publication. All authors contributed to the revision of the manuscript. CRK wrote the manuscript draft, processed the EHR data, and did the statistical analysis. CRK, BAF, ST, and MA implemented the machine-learning web application. ABA created the original analysis plan, contributed to the conception of the work, and analysed data for and prepared DSMB reports. CRK and ABA directly accessed and verified the underlying patient data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. BAF and CRK directly accessed and verified the case-review, and alert data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. SHG, BT, OH, PK, BH, TSW, MCP, JA, and MSA contributed to the conception of the work, implementation of the intervention, and interpretation of the results. TB contributed to the implementation of the intervention and regulatory oversight. SG, AM, DM, MAV, and EK contributed to the implementation of the intervention and data acquisition. AK conducted EHR data acquisition and intervention informatics implementation. MSA lead the conception, design, and implementation of the work. MSA, TK, BAF, ABA, and CRK contributed to the interpretation of the data.

## **Acknowledgements**

Members of the ACTFAST Study Group who contributed to data acquisition or other support of the implementation are provided in the Supplement.

**Declaration of interests**: We declare no competing interests.

## **Funding**

This work was supported by the National Institute of Nursing Research (R01 NR017916 to Dr. Avidan) and departmental funding from Washington University in St Louis School of Medicine. The investigators were also supported by National Institutes of Health training awards TR002346 (Dr King) and T32GM108539 (Drs King and Fritz) and funding from the Foundation for Anesthesia Education and Research (MRT08152020 to Dr Fritz).

The funding organization(s) had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

**Data Sharing Statement**: The Washington University Human Research Protection Office did not permit sharing of patient level data due to enrolment with a waiver of consent. Summary data is available at the clinicaltrials.gov registration.

First Name	Last Name	Research Role	Degree	Clinician Role
Michael	Avidan	PI	MD	Attending
Joanna	Abraham	Investigator	PHD	N/A
Maureen	Arends	Support		N/A
Kara	Battig	Clinician	BSN, RN	CRNA
Arbi	Ben Abdallah	Investigator	DES, PHD	N/A
Danielle	Benematti	Clinician	BS, BSN	CRNA
George	Benzinger	Clinician	MD, PHD	Attending
Mara	Bollini	Investigator	BA, BSN, MHA	N/A
Margaret	Bradley	Clinician	BSN	CRNA
Thaddeus	Budelier	Investigator	MD, MSF	N/A
Kathryn	Cass	Clinician	CRNA	CRNA
Yixin	Chen	Investigator	PHD	N/A
Daniel	Eddins	Clinician	BS, BSN, RN	CRNA
David	Eisenbath	Clinician	BSN, MSN	CRNA
Daniel	Emmert	Clinician	PHD, MD	Attending
Ellen	Fischbach	Support	BS, CCRP	N/A
Bradley	Fritz	Investigator	MD	Attending
Jason	Gillihan	Clinician	MD	Attending
Marie	Goez	Clinician	RN, DNP	CRNA
Shreya	Goswami	Coordinator	MBBS, DNB	N/A
Thomas	Graetz	Clinician	MD	Attending
Stephen	Gregory	Clinician	MD	Attending
Ryan	Guffey	Clinician	MD	Attending
Charles	Hantler	Clinician	MD	Attending
Peter	Haw	Clinician	BSN	CRNA
Daniel	Helsten	Clinician	MD	Attending
Bernadette	Henrichs	Clinician	PHD	CRNA
Erin	Herrera	Clinician	MSN	CRNA
Omokhaye	Higo	Clinician	MD	Attending

Robert	Hovis	Clinician	CRNA	CRNA
Gary	Hubbard	Clinician	MS	CRNA
Rocco	Hueneke	Clinician	MD	Attending
lvan	Kangrga	Clinician	MD, PHD	Attending
Thomas	Kannampallil	Investigator	PHD	N/A
Menelaos	Karanikolas	Clinician	MD, MPH	Attending
Christopher	King	Investigator	MD, PHD	Attending
Holly	Kirkpatrick	Clinician	BSN	CRNA
Justin	Knittel	Clinician	MD	Attending
Helga	Komen	Clinician	MD	Attending
Alexander	Kronzer	Support	ВА	N/A
Anand	Lakshminarasimhachar	Clinician	MD, MD	Attending
Alyssa	McClellan	Clinician	BSN	CRNA
Sherry	McKinnon	Support	BS, MS, CCRP	N/A
Alicia	Meng	Support	ВА	N/A
Alexander	Mohrmann	Clinician	BSN	CRNA
David	Monks	Clinician	MBChB FRCA MSc	Attending
Mary	Politi	Investigator	PHD	N/A
Debra	Pulley	Clinician	MD	Attending
Rashmi	Rathor	Clinician	MD	Attending
Andrea	Reidy	Clinician	MD	Attending
Cameron	Ritter	Clinician	BS, BSN, MS	CRNA
Elvira	Sayfutdinova	Clinician	BSN	SRNA
Craig	Schadler	Clinician	BSN	CRNA
Elizabeth	Schappe	Clinician	MS	CRNA
Tracey	Stevens	Clinician	MD	Attending
Marko	Todorovic	Clinician	MD	Attending
Brian	Torres	Clinician	MS, DNP, CRNA CRNA	
Bradley	Uding	Clinician	BS, BSN	CRNA
Brandon	Ufert	Clinician	RN	SRNA

			MBBS,FRCA(UK),FCAR	
Swarup	Varaday	Clinician	I(IRELAND), MD	Attending
Troy	Wildes	Investigator	MD	Attending
William	Wise	Clinician	MSN	CRNA
Rachel	Wolfe	Investigator	PharmD	N/A
Sennaraj	Balasubramanian	Clinician	MD	Attending
Anuradha	Borle	Clinician	MD	Attending
Jamie	Brown-Shpigel	Clinician	MD	Attending
Jane	Exler	Clinician	BS	CRNA
Khatera	Najrabi	Clinician	BSN	CRNA
David	Potter	Clinician	BSN, MBA	CRNA
Sarah	Sillery	Clinician	MSN	CRNA
Kate	Silver	Clinician	MSN	CRNA
Preet	Mohinder Singh	Clinician	MD	Attending
Melanie	Somercik	Clinician	MSN	CRNA
Bradley	Gerlach	Clinician	MSN	CRNA
Gregory	Miller	Clinician	MD	Resident
Adrienne	Nations	Clinician	BSN	CRNA
Lindsey	Schurter	Clinician	BSN	SRNA
Dean	Thorsen	Clinician	MD	Resident
Brian	Weber	Clinician	MD	Resident
Mark	Willingham	Clinician	BS, MD	Attending
Allison	Yu	Clinician	MD	Resident
Joseph	Balassi	Clinician	BSN	CRNA
Yunwei	Chen	Clinician	MD	Attending
Mathew	Gielow	Clinician	BSN	CRNA
Arianna	Montes de Oca	Coordinator	MD	N/A
Melissa	Milbrandt	Support	МВА, МНА	N/A
Mary	Zerlan	Clinician	DNP	CRNA
Courtney	Hardy	Clinician	MD	Attending
Divya	Mehta	Coordinator	MD	N/A

Ben	Snyders	Clinician	MSN	CRNA
Mohamed	Abdelhack	Support	PhD	N/A
Gregory	Feilner	Clinician	MSN,DNP	CRNA
Elyse	Kaestner	Clinician	MSN	CRNA
Molly	Barry	Clinician	MSN	CRNA
Vanya	Tumati	Clinician	MD	Resident
David	Carr	Clinician	MD	Resident
Andrew	Tran	Clinician	MD	Resident
Phillip	Taylor	Clinician	MD	Resident
Elizabeth	Schroeder	Clinician	MSN	CRNA
Jonathan	Jocum	Clinician	MD	Attending
Bruno	Maranhao	Clinician	MD, PHD	Resident
Hawa	Abubakar	Clinician	MD	Resident
Daniel	Fernandez	Clinician	MD	Resident
Danish	Jaffer	Clinician	MD	Resident
Andrew	Pauszek	Clinician	MD	Resident
Ellen	Dekleva	Clinician	NA	SRNA
Catherine	Foster	Clinician	MD	Attending
Victoria	Koke	Clinician	MSN	CRNA
Megan	Taylor	Clinician	DNAP	CRNA
Benjamin	French	Clinician	MD	Resident
Benjamin	Fuller	Clinician	MD	Resident
Melissa	Milnor	Clinician	BSN	SRNA
Jessica	Sanford	Clinician	MD	Resident
Sandhya	Tripathi	Support	PhD	N/A
Fillmore	Gerardson Almiron	Clinician	NA	SRNA
Tamanna	Chang	Clinician	MD	Resident
Cynthia	Clark-Bumgarner	Clinician	NA	SRNA
Megan	Dewey	Clinician	MD	Resident
Ashley	Harrell	Clinician	BSN	SRNA
Claira	Sousa	Clinician	BSN	SRNA

Aldin	Turan	Clinician	BSN	SRNA
Jessica	Shah	Clinician	MSN	CRNA
Furqaan	Sadiq	Clinician	MD	Resident
Mingchun	Liu	Clinician	MD	Resident
Jing	Zhong	Clinician	MD	Resident
Jason	Han	Clinician	MD	Resident
Austin	Lohse	Clinician	MD	Resident
Jared	Wilmoth	Clinician	MD	Resident
James	Wirthlin	Clinician	MD	Resident
Mayank	Agarwal	Clinician	MD	Resident
Jooyoung	Maeng	Clinician	MD	Resident
Brennan	McMillan	Clinician	MD	Resident
David	Moquin	Clinician	MD	Resident
Shiv	Rawal	Clinician	MD	Resident
Alexander	Scott	Clinician	MD	Resident
Sara	Fisher	Support	МНА	N/A
Frank	Bougher	Clinician	BSN	SRNA
Suzanne	Frattini	Clinician	MHS	CRNA
Mallory	Light	Clinician	MSN	SRNA
Katherine	Mette	Clinician	BS	SRNA
Benjamin	Thomas	Clinician	BSN	SRNA
India	Johnson	Clinician	DNAP	CRNA
Ramya	Baddigam	Clinician	MD	Resident
Emily	Davenport	Clinician	BSN	SRNA
Bethany	Geisler	Clinician	RN	SRNA
Robert	Graham	Clinician	RN	SRNA
Hunter	Niemeyer	Clinician	BSN	SRNA
Britni	Tharp	Clinician	BSN	SRNA
Christian	Guay	Clinician	MD	Resident
Micael	Bethel	Clinician	MD	Resident
Steven	Hedgecorth	Clinician	MD	Resident

Rida	Chaudhry	Clinician	MD	Resident
Krishna	Bhat	Clinician	MD	Resident
Michael	McLean	Clinician	BSN	SRNA
Jonathan	Ford	Clinician	MD	Resident
Joseph	Avery	Clinician	MD	Resident
Kiran	Kamath	Clinician	MD	Resident
Stephan	Diljak	Clinician	MD	Resident
Jiaxin	Huang	Clinician	MD	Resident
Zachary	Jergensen	Clinician	MD	Resident
Sheila	Sullivan	Clinician	MD	Resident
Bethany	Pennington	Investigator	PharmD	N/A
Kim	My Li	Clinician	MD	Resident
David	Rasche	Clinician	MD	Resident
Ryan	Pieterick	Clinician	MD	Resident
Ziyan	Song	Clinician	MD	Resident
Taylor	Crittenden	Clinician	BSN	SRNA
Paul	Kerby	Clinician	MBBS	Attending
Leander	Lee	Clinician	MD	Resident
Lingshu	Liu	Clinician	MD	Resident
Ruchik	Patel	Clinician	MD	Resident
Jonathan	Rich	Clinician	MD	Resident
Manjaap	Sidhu	Clinician	MD	Resident
Peter	Szatkowski	Clinician	MD	Resident
Brandon	White	Clinician	MD	Resident
Meghan	Woodham	Clinician	BSN	SRNA
Lauren	Schoolfield	Clinician	BSN	SRNA
Benjamin	Stivers	Clinician	MD	Resident
Madeline	Wilson	Clinician	BSN	SRNA
Neil	Frydrych	Clinician	BSN	SRNA
Amanuel	Gebeyehu	Clinician	BSN	SRNA
Ottavia	Green	Clinician	MD	Resident

Evangelos Karanikolas Coordinator MD N/A  Jessica Morrow Clinician DNP CRNA  Mark Hanak Clinician MD Reside  Lauren Lagrimas Clinician MD Reside  Grace Huang Support BS N/A  Miguel Valdez Coordinator MD N/A  Maria Angelica Baquero Clinician NA CRNA  Abby Bisch Clinician NA CRNA  Belma Kulovac Clinician NA CRNA  Monika Martinek Support BS N/A  Jonathan Zoller Clinician MD Attend  Anchal Bansal Clinician MD Reside  Sarah Perez Support MSN N/A  Micaela Clark Clinician MD Reside  Jordan Nations Clinician RN  CRNA  Clinician MD Reside  Clinician MD Reside  Clark Clinician MD Reside  Jordan Nations Clinician RN  CRNA  CRNA  CRNA  Clinician MD Reside  Clinician RN  Clinician RN  CRNA  CRNA  Clinician RN  CRNA  CRNA  CRNA  Clinician RN  CRNA  CRNA  CRNA  CLinician CRNA  C	BSI	cian		BSN,DNP	CRNA
Mary Kirsch Clinician DNAP CRNA Meghan Marshall Clinician BSN SRNA Sean Pottenger Clinician BSN SRNA Todd Rackohn Clinician MD Reside Evangelos Karanikolas Coordinator MD N/A Jessica Morrow Clinician DNP CRNA Mark Hanak Clinician MD Reside Lauren Lagrimas Clinician MD Reside Grace Huang Support BS N/A Miguel Valdez Coordinator MD N/A Maria Angelica Baquero Clinician NA CRNA Abby Bisch Clinician NA CRNA Monika Martinek Support BS N/A Monika Martinek Support BS N/A Monika Martinek Support BS N/A  Monika Martinek Support BS N/A  Monika Martinek Support BS N/A  Corna Monika Martinek Support BS N/A  Moni	BSI	cian		BSN	SRNA
Meghan Marshall Clinician BSN SRNA Sean Pottenger Clinician BSN SRNA Todd Rackohn Clinician MD Reside Evangelos Karanikolas Coordinator MD N/A Jessica Morrow Clinician DNP CRNA Mark Hanak Clinician MD Reside Lauren Lagrimas Clinician MD Reside Grace Huang Support BS N/A Miguel Valdez Coordinator MD N/A Maria Angelica Baquero Clinician NA CRNA Abby Bisch Clinician NA CRNA Monika Martinek Support BS N/A Monika Martinek Support BS N/A  Monika Martinek Support MSN N/A  Monika Martinek Support MD N/A  Monika MARTINE MD N/A  Monika Martinek Support MD N/A  Monika MD N/	BSI	cian		BSN	SRNA
Sean Pottenger Clinician BSN SRNA Todd Rackohn Clinician MD Reside Evangelos Karanikolas Coordinator MD N/A Jessica Morrow Clinician DNP CRNA Mark Hanak Clinician MD Reside Lauren Lagrimas Clinician MD Reside Grace Huang Support BS N/A Miguel Valdez Coordinator MD N/A Maria Angelica Baquero Clinician NA CRNA Abby Bisch Clinician NA CRNA Monika Martinek Support BS N/A Jonathan Zoller Clinician NA CRNA Jonathan Zoller Clinician MD Attend Anchal Bansal Clinician MD Reside Sarah Perez Support MSN N/A Micaela Clark Clinician MD Reside Jordan Nations Clinician RN SRNA Kate Pozzo Clinician CRNA CRNA Julia Downey Clinician DNAP CRNA	DN	cian		DNAP	CRNA
Todd Rackohn Clinician MD Reside Evangelos Karanikolas Coordinator MD N/A Jessica Morrow Clinician DNP CRNA Mark Hanak Clinician MD Reside Lauren Lagrimas Clinician MD Reside Grace Huang Support BS N/A Miguel Valdez Coordinator MD N/A Maria Angelica Baquero Clinician NA CRNA Abby Bisch Clinician NA CRNA Monika Martinek Support BS N/A Jonathan Zoller Clinician NA CRNA Leon Du Toit Clinician MD Attend Anchal Bansal Clinician MD Reside Sarah Perez Support MSN N/A Micaela Clark Clinician MD Reside Jordan Nations Clinician RN SRNA Kate Pozzo Clinician DNAP CRNA	BSI	cian		BSN	SRNA
Evangelos Karanikolas Coordinator MD N/A  Jessica Morrow Clinician DNP CRNA  Mark Hanak Clinician MD Reside  Lauren Lagrimas Clinician MD Reside  Grace Huang Support BS N/A  Miguel Valdez Coordinator MD N/A  Maria Angelica Baquero Clinician NA CRNA  Abby Bisch Clinician NA CRNA  Belma Kulovac Clinician NA CRNA  Monika Martinek Support BS N/A  Jonathan Zoller Clinician MD Attend  Anchal Bansal Clinician MD Reside  Sarah Perez Support MSN N/A  Micaela Clark Clinician MD Reside  Jordan Nations Clinician RN  CRNA  CRNA  Clinician MD Reside  Clordan Nations Clinician MD Reside  Jordan Nations Clinician RN  CRNA  CRNA  Clinician MD Reside  Clordan Nations Clinician RN  CRNA  CRNA  CRNA  Clinician MD Reside  Clordan Nations Clinician RN  CRNA  CRNA  CRNA  Clinician MD Reside  Clordan Nations Clinician RN  CRNA	BSI	cian		BSN	SRNA
Dessica Morrow Clinician DNP CRNA Mark Hanak Clinician MD Reside Lauren Lagrimas Clinician MD Reside Grace Huang Support BS N/A Miguel Valdez Coordinator MD N/A Maria Angelica Baquero Clinician NA CRNA Abby Bisch Clinician NA CRNA Belma Kulovac Clinician NA CRNA Monika Martinek Support BS N/A Jonathan Zoller Clinician MD Attend Anchal Bansal Clinician MD Attend Anchal Bansal Clinician MD Reside Sarah Perez Support MSN N/A Micaela Clark Clinician BSN SRNA Christine Johnson Clinician RN SRNA CRNA CRNA CRNA CRNA CRNA CRNA CRNA CRNA CRNA	ΜE	cian		MD	Resident
Mark Hanak Clinician MD Reside Lauren Lagrimas Clinician MD Reside Grace Huang Support BS N/A Miguel Valdez Coordinator MD N/A Maria Angelica Baquero Clinician NA CRNA Abby Bisch Clinician NA CRNA Belma Kulovac Clinician NA CRNA Monika Martinek Support BS N/A Jonathan Zoller Clinician MD Attend Anchal Bansal Clinician MD Reside Sarah Perez Support MSN N/A Micaela Clark Clinician MD Reside Jordan Nations Clinician BSN SRNA Christine Johnson Clinician RN SRNA Julia Downey Clinician DNAP CRNA Julia Downey Clinician DNAP CRNA Julia Downey Clinician DNAP CRNA Jonathan CRNA Julia Downey Clinician DNAP CRNA Julia Downey Clinician DNAP CRNA Julia Downey Clinician MD Reside	MΕ	dinator	or	MD	N/A
Lauren Lagrimas Clinician MD Reside Grace Huang Support BS N/A Miguel Valdez Coordinator MD N/A Maria Angelica Baquero Clinician NA CRNA Abby Bisch Clinician NA CRNA Belma Kulovac Clinician NA CRNA Monika Martinek Support BS N/A Jonathan Zoller Clinician MD Attend Leon Du Toit Clinician MD Attend Anchal Bansal Clinician MD Reside Sarah Perez Support MSN N/A Micaela Clark Clinician MD Reside Jordan Nations Clinician BSN SRNA Christine Johnson Clinician RN SRNA Kate Pozzo Clinician DNAP CRNA Julia Downey Clinician DNAP CRNA Jackie Yu Clinician MD Reside	DN	cian		DNP	CRNA
Grace Huang Support BS N/A  Miguel Valdez Coordinator MD N/A  Maria Angelica Baquero Clinician NA CRNA  Abby Bisch Clinician NA CRNA  Belma Kulovac Clinician NA CRNA  Monika Martinek Support BS N/A  Jonathan Zoller Clinician MD Attend  Anchal Bansal Clinician MD Attend  Anchal Bansal Clinician MD Reside  Sarah Perez Support MSN N/A  Micaela Clark Clinician MD Reside  Jordan Nations Clinician BSN SRNA  Christine Johnson Clinician RN SRNA  Kate Pozzo Clinician CRNA CRNA  Jackie Yu Clinician DNAP CRNA  Jackie Yu Clinician MD Reside	ΜE	cian		MD	Resident
Miguel Valdez Coordinator MD N/A  Maria Angelica Baquero Clinician NA CRNA  Abby Bisch Clinician NA CRNA  Belma Kulovac Clinician NA CRNA  Monika Martinek Support BS N/A  Jonathan Zoller Clinician MD Attend  Leon Du Toit Clinician MD Attend  Anchal Bansal Clinician MD Reside  Sarah Perez Support MSN N/A  Micaela Clark Clinician MD Reside  Jordan Nations Clinician BSN SRNA  Christine Johnson Clinician RN SRNA  Kate Pozzo Clinician DNAP CRNA  Jackie Yu Clinician DNAP CRNA  Jackie	ME	cian		MD	Resident
Maria Angelica Baquero Clinician NA CRNA Abby Bisch Clinician NA CRNA Belma Kulovac Clinician NA CRNA Monika Martinek Support BS N/A Jonathan Zoller Clinician MD Attend Leon Du Toit Clinician MD Attend Anchal Bansal Clinician MD Reside Sarah Perez Support MSN N/A Micaela Clark Clinician MD Reside Jordan Nations Clinician BSN SRNA Christine Johnson Clinician RN SRNA Kate Pozzo Clinician CRNA CRNA Julia Downey Clinician DNAP CRNA Jackie Yu Clinician MD Reside	BS	ort		BS	N/A
Abby Bisch Clinician NA CRNA Belma Kulovac Clinician NA CRNA Monika Martinek Support BS N/A Jonathan Zoller Clinician MD Attend Leon Du Toit Clinician MD Attend Anchal Bansal Clinician MD Reside Sarah Perez Support MSN N/A Micaela Clark Clinician MD Reside Jordan Nations Clinician BSN SRNA Christine Johnson Clinician RN SRNA Kate Pozzo Clinician CRNA CRNA Julia Downey Clinician MD Reside	ΜE	dinator	or	MD	N/A
Belma Kulovac Clinician NA CRNA Monika Martinek Support BS N/A Jonathan Zoller Clinician MD Attend Leon Du Toit Clinician MD Attend Anchal Bansal Clinician MD Reside Sarah Perez Support MSN N/A Micaela Clark Clinician MD Reside Jordan Nations Clinician BSN SRNA Christine Johnson Clinician RN SRNA Kate Pozzo Clinician CRNA CRNA Julia Downey Clinician DNAP CRNA Jackie Yu Clinician MD Reside	NA	cian		NA	CRNA
Monika Martinek Support BS N/A  Jonathan Zoller Clinician MD Attend  Leon Du Toit Clinician MD Attend  Anchal Bansal Clinician MD Reside  Sarah Perez Support MSN N/A  Micaela Clark Clinician MD Reside  Jordan Nations Clinician BSN SRNA  Christine Johnson Clinician RN SRNA  Kate Pozzo Clinician CRNA CRNA  Julia Downey Clinician DNAP CRNA  Jackie Yu Clinician MD Reside	NA	cian		NA	CRNA
Jonathan Zoller Clinician MD Attend Leon Du Toit Clinician MD Attend Anchal Bansal Clinician MD Reside Sarah Perez Support MSN N/A Micaela Clark Clinician MD Reside Jordan Nations Clinician BSN SRNA Christine Johnson Clinician RN SRNA Kate Pozzo Clinician CRNA CRNA Julia Downey Clinician DNAP CRNA Jackie Yu Clinician MD Reside	NA	cian		NA	CRNA
Leon Du Toit Clinician MD Attend Anchal Bansal Clinician MD Reside Sarah Perez Support MSN N/A Micaela Clark Clinician MD Reside Jordan Nations Clinician BSN SRNA Christine Johnson Clinician RN SRNA Kate Pozzo Clinician CRNA CRNA Julia Downey Clinician DNAP CRNA Jackie Yu Clinician MD Reside	BS	ort		BS	N/A
Anchal Bansal Clinician MD Reside Sarah Perez Support MSN N/A Micaela Clark Clinician MD Reside Jordan Nations Clinician BSN SRNA Christine Johnson Clinician RN SRNA Kate Pozzo Clinician CRNA CRNA Julia Downey Clinician DNAP CRNA Jackie Yu Clinician MD Reside	MΕ	cian		MD	Attending
Sarah Perez Support MSN N/A  Micaela Clark Clinician MD Reside  Jordan Nations Clinician BSN SRNA  Christine Johnson Clinician RN SRNA  Kate Pozzo Clinician CRNA CRNA  Julia Downey Clinician DNAP CRNA  Jackie Yu Clinician MD Reside	MΕ	cian		MD	Attending
Micaela Clark Clinician MD Reside  Jordan Nations Clinician BSN SRNA  Christine Johnson Clinician RN SRNA  Kate Pozzo Clinician CRNA CRNA  Julia Downey Clinician DNAP CRNA  Jackie Yu Clinician MD Reside	MΕ	cian		MD	Resident
Jordan Nations Clinician BSN SRNA Christine Johnson Clinician RN SRNA Kate Pozzo Clinician CRNA CRNA Julia Downey Clinician DNAP CRNA Jackie Yu Clinician MD Reside	MS	ort		MSN	N/A
Christine Johnson Clinician RN SRNA Kate Pozzo Clinician CRNA CRNA Julia Downey Clinician DNAP CRNA Jackie Yu Clinician MD Reside	MΕ	cian		MD	Resident
Kate Pozzo Clinician CRNA CRNA Julia Downey Clinician DNAP CRNA Jackie Yu Clinician MD Reside	BSI	cian		BSN	SRNA
Julia Downey Clinician DNAP CRNA Jackie Yu Clinician MD Reside	RN	cian		RN	SRNA
Jackie Yu Clinician MD Reside	CRI	cian		CRNA	CRNA
	DN	cian		DNAP	CRNA
Adalas and a same a same and a sa	ME	cian		MD	Resident
Mohanapriya Arumugam Coordinator MD N/A	ME	dinator	or	MD	N/A
Natalie Profumo Clinician DNP CRNA	DN	cian		DNP	CRNA
Chelsea Curless Clinician CRNA CRNA	CRI	cian		CRNA	CRNA
Eleanor Bilhorn Clinician CRNA CRNA	CRI	cian		CRNA	CRNA

Lokesh	Sharma	Clinician	MD	Resident
Pratyush	Sontha	Support	ВА	N/A
Laura	Cavallone	Clinician	MD	Attending
William	Varnum	Clinician	MSN	CRNA
Martha	Sabino	Clinician	BSN	SRNA
Muthuraj	Kanakaraj	Clinician	MD	Attending
Muhan	Zhang	Support	PhD	

#### **REFERENCES**

- 1. Guinemer, C. *et al.* Telemedicine in Intensive Care Units: Scoping Review. *J. Med. Internet Res.* **23**, e32264 (2021).
- Subramanian, S. et al. Tele-Critical Care: An Update From the Society of Critical Care Medicine Tele-ICU Committee. Crit. Care Med. 48, 553–561 (2020).
- 3. Ofoma, U. R. *et al.* Characteristics of U.S. Acute Care Hospitals That Have Implemented Telemedicine Critical Care. *Crit. Care Explor.* **3**, e0468 (2021).
- 4. Caples, S. M. Intensive Care Unit Telemedicine Care Models. Crit. Care Clin. 35, 479–482 (2019).
- Spies, C. D. et al. Effectiveness of an intensive care telehealth programme to improve process quality
   (ERIC): a multicentre stepped wedge cluster randomised controlled trial. Intensive Care Med. 49, 191–204
   (2023).
- Kahn, J. M. et al. ICU Telemedicine and Critical Care Mortality: A National Effectiveness Study. Med. Care
   319–325 (2016).
- 7. Bridges, K. H., McSwain, J. R. & Wilson, P. R. To Infinity and Beyond: The Past, Present, and Future of Tele-Anesthesia. *Anesth. Analg.* **130**, 276–284 (2020).
- 8. Cone, S. W., Gehr, L., Hummel, R. & Merrell, R. C. Remote anesthetic monitoring using satellite telecommunications and the Internet. *Anesth. Analg.* **102**, 1463–1467 (2006).
- 9. Cone, S. W. *et al.* Case report of remote anesthetic monitoring using telemedicine. *Anesth. Analg.* **98**, 386–388 (2004).
- 10. Miyashita, T. et al. A pilot study of tele-anaesthesia by virtual private network between an island hospital and a mainland hospital in Japan. *J. Telemed. Telecare* **21**, 73–79 (2015).
- 11. Fiadjoe, J. *et al.* Telemedicine consultation and monitoring for pediatric liver transplant. *Anesth. Analg.* **108**, 1212–1214 (2009).
- 12. Saksa, D. *et al.* Telemedicine-Based Perioperative Management of Pheochromocytoma in a Patient With Von Hippel Lindau Disease: A Case Report. *AA Pract.* **15**, e01378 (2021).

- 13. Kheterpal, S., Shanks, A. & Tremper, K. K. Impact of a Novel Multiparameter Decision Support System on Intraoperative Processes of Care and Postoperative Outcomes. *Anesthesiology* **128**, 272–282 (2018).
- 14. Abraham, J. *et al.* An ethnographic study on the impact of a novel telemedicine-based support system in the operating room. *J. Am. Med. Inform. Assoc. JAMIA* **29**, 1919–1930 (2022).
- 15. King, C. R. et al. An Intraoperative Telemedicine Program to Improve Perioperative Quality Measures: The ACTFAST-3 Randomized Clinical Trial. *JAMA Netw. Open* **6**, e2332517 (2023).
- Murray-Torres, T. et al. Anesthesiology Control Tower-Feasibility Assessment to Support Translation (ACTFAST): Mixed-Methods Study of a Novel Telemedicine-Based Support System for the Operating Room. JMIR Hum. Factors 6, e12155 (2019).
- 17. Abraham, J. et al. Exploring patient perspectives on telemedicine monitoring within the operating room. *Int. J. Med. Inf.* **156**, 104595 (2021).
- 18. Abraham, J. *et al.* Integrating machine learning predictions for perioperative risk management: Towards an empirical design of a flexible-standardized risk assessment tool. *J. Biomed. Inform.* **137**, 104270 (2023).
- 19. Fritz, B. A. *et al.* Deep-learning model for predicting 30-day postoperative mortality. *Br. J. Anaesth.* **123**, 688–695 (2019).
- 20. Fritz, B. A. *et al.* User-Centered Design of a Machine Learning Dashboard for Prediction of Postoperative Complications. *Anesth. Analg.* (2023) doi:10.1213/ANE.0000000000006577.
- 21. Xue, B. *et al.* Use of Machine Learning to Develop and Evaluate Models Using Preoperative and Intraoperative Data to Identify Risks of Postoperative Complications. *JAMA Netw. Open* **4**, e212240 (2021).
- 22. Fritz, B. A. et al. Effect of Machine Learning on Accuracy of Intraoperative Anesthesiology Clinician Prediction of Postoperative Complications: The ORACLE (Outcome Risk Assessment with Computer Learning Enhancement) Trial. Submited (2024).

- 23. King, C. R. et al. Protocol for the Effectiveness of an Anesthesiology Control Tower System in Improving Perioperative Quality Metrics and Clinical Outcomes: the TECTONICS randomized, pragmatic trial. F1000Research 8, 2032 (2019).
- 24. Zeileis, A., Köll, S. & Graham, N. Various Versatile Variances: An Object-Oriented Implementation of Clustered Covariances in R. *J. Stat. Softw.* **95**, 1–36 (2020).
- 25. Romano, J. P. & Wolf, M. Efficient computation of adjusted p-values for resampling-based stepdown multiple testing. *Stat. Probab. Lett.* **113**, 38–40 (2016).
- 26. Ioannidis, J. P. A. The Proposal to Lower P Value Thresholds to .005. JAMA 319, 1429-1430 (2018).
- 27. Ranzani, O. et al. Statistical analysis of a cluster-randomized clinical trial on adult general intensive care units in Brazil: TELE-critical care verSus usual Care On ICU PErformance (TELESCOPE) trial. Rev. Bras. Ter. Intensiva 34, 87–95 (2022).
- 28. van Eijk, M. M. et al. Routine use of the confusion assessment method for the intensive care unit: a multicenter study. Am. J. Respir. Crit. Care Med. 184, 340–344 (2011).
- Saager, L. et al. Do It Often, Do It Better: Association Between Pairs of Experienced Subspecialty
   Anesthesia Caregivers and Postoperative Outcomes. A Retrospective Observational Study. Anesth. Analg.
   132, 866–877 (2021).